Prognostic inflammatory–immune score-based risk stratification optimizes adjuvant therapy for non-gastric gastrointestinal stromal tumors: a multicenter study - Poll - MDSpire

Prognostic inflammatory–immune score-based risk stratification optimizes adjuvant therapy for non-gastric gastrointestinal stromal tumors: a multicenter study

  • By

  • Zhiming Cai

  • Zhengnan Xu

  • Huimei Lin

  • Huibin Liu

  • Zihan Lin

  • Jinhu Chen

  • Shichai Hong

  • Weibin Song

  • Xinyu Chen

  • Yanchang Xu

  • Zhenrong Yang

  • Yongjian Zhou

  • June 2, 2026

  • 0 min

Share

Original Source(s)

Prognostic inflammatory–immune score-based risk stratification optimizes adjuvant therapy for non-gastric gastrointestinal stromal tumors: a multicenter study

  • by Zhiming Cai, Zhengnan Xu, Huimei Lin, Huibin Liu, Zihan Lin, Jinhu Chen, Shichai Hong, Weibin Song, Xinyu Chen, Yanchang Xu, Zhenrong Yang, Yongjian Zhou

  • June 2, 2026

Related Content

Characteristics and risk factors of immune-related adverse events in patients receiving immune checkpoint inhibitor combination therapy

A case report of thyroid-like low-grade nasopharyngeal papillary adenocarcinoma with literature review

Clinical benefit of paclitaxel/carboplatin plus bevacizumab with zoledronic acid in pulmonary epithelioid hemangioendothelioma complicated by hypertrophic pulmonary osteoarthropathy and cardiac tamponade: a case report